Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Sales: 2019-2025

Historic Return on Sales for BridgeBio Pharma (BBIO) over the last 6 years, with Sep 2025 value amounting to -2.16%.

  • BridgeBio Pharma's Return on Sales fell 27.00% to -2.16% in Q3 2025 from the same period last year, while for Sep 2025 it was -2.16%, marking a year-over-year decrease of 27.00%. This contributed to the annual value of -2.45% for FY2024, which is 6777.00% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Return on Sales of -2.16% as of Q3 2025, which was up 31.49% from -3.15% recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Return on Sales peaked at 283.61% during Q1 2021, and registered a low of -105.02% during Q2 2023.
  • Over the past 3 years, BridgeBio Pharma's median Return on Sales value was -3.15% (recorded in 2025), while the average stood at -24.43%.
  • Its Return on Sales has fluctuated over the past 5 years, first surged by 29,250bps in 2021, then slumped by 33,820bps in 2022.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Return on Sales stood at -59.40% in 2021, then skyrocketed by 5,186bps to -7.54% in 2022, then crashed by 6,455bps to -72.09% in 2023, then spiked by 6,989bps to -2.19% in 2024, then fell by 27bps to -2.16% in 2025.
  • Its Return on Sales was -2.16% in Q3 2025, compared to -3.15% in Q2 2025 and -4.78% in Q1 2025.